Poll Results Spotlight Key GU Cancer Abstracts Driving Anticipation Ahead of ESMO 2025 #ESMO25 #GenitourinaryCancers www.onclive.com/view/poll-re...

Roswell Park Care Network Expands with New Thoracic Surgery Services and Faculty @roswellpark.bsky.social #ThoracicOncology #surgery www.onclive.com/view/roswell...

Revumenib Joins NCCN Guidelines for NPM1-Mutated R/R Acute Myeloid Leukemia #leusm #hematology www.onclive.com/view/revumen...

Stenoparib Monotherapy Yields Potential OS Benefit in Platinum-Resistant Ovarian Cancer #ovca #oncology www.onclive.com/view/stenopa...

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL #LBCL #lymsm @stanfordmedicine.bsky.social www.onclive.com/view/kite-36...

FDA Removes REMS Program for Vandetanib for Medullary Thyroid Cancer @fda.gov #hncsm #oncology www.onclive.com/view/fda-rem...

We want to thank David Scarisbrick, PhD, of @rutgerscancer.bsky.social for taking the time for an interview to discuss oncofunctional balance in management of brain tumors. Be on the lookout for highlights from the interview at onclive.com #oncology #glioma

Thank you to Nicholas DeNunzio, MD, PhD, of @rutgerscancer.bsky.social for making time for an interview to discuss notable updates in radiation therapies for patients with brain tumors. Check back to onclive.com later on for interview highlights! #oncology #glioma

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer @cityofhope.bsky.social #pancsm #oncology www.onclive.com/view/first-l...

Thanks to Morana Vojnic, MD, MBA of @rutgerscancer.bsky.social who gave an excellent interview on clinical updates in primary and secondary brain tumors. Look out for clips from the interview on onclive.com #oncology #glioma

🚨 BREAKING NEWS 🚨: @fda.gov Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer Read up on the approval: www.onclive.com/view/fda-app...

Nehal Parikh, MD, of @rutgerscancer.bsky.social dropped by for an interview to discuss advances in pediatric high-grade brain tumors, stay tuned to onclive.com for clips from the conversation. #oncology #glioma

Mitazalimab Plus Chemo Demonstrates Potential OS Benefit in Previously Untreated Metastatic #PancreaticCancer #oncology www.onclive.com/view/mitazal...

A big thanks to our first interviewee of the day, Jonathan H. Sherman, MD, of @rutgerscancer.bsky.social who discussed new innovations in surgical brain tumor management! Check out hubs.li/Q03L11R70 later for highlights from the interview #oncology #glioma

Dana-Farber Cancer Institute and Northeastern University Partner to Train the Next Generation of Clinical-Ready Oncology Nurses @rpozzar.bsky.social @danafarber.bsky.social @northeasternu.bsky.social #oncology www.onclive.com/view/dana-fa...

The presentations are in full swing here at the International Brain Tumor Symposium! Stay tuned to hubs.li/Q03L0Hh90 for updates from the meeting. @rutgerscancer.bsky.social #oncology #glioma

A400/EP0031 NDA Accepted for Review in China for RET Fusion–Positive NSCLC #LCSM #NSCLC #LungCancer www.onclive.com/view/a400-ep...

The FDA Grants Utidelone Injection Orphan Drug Designation for #PancreaticCancer #oncology www.onclive.com/view/fda-gra...

Avantect Multi-Cancer and Ovarian Cancer Detection Tests Achieve UKCA Marking #OvarianCancer #Oncology #gyncsm www.onclive.com/view/avantec...

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL #CLL #Hematology www.onclive.com/view/zanubru...

We are live in New Brunswick for the First Annual International Brain Tumor Symposium! Looking forward to an exciting day of presentations covering the latest updates in neuro-oncology. Stay tuned to hubs.li/Q03KZF9C0 for our coverage of the meeting #oncology #glioma

With the #ESMO25 just a few weeks away, we asked experts to help preview the most anticipated breast cancer abstracts in the program. Sign up and read exclusive insights ahead of @myesmo.bsky.social 2025 #bcsm www.onclive.com/view/breast-...

Timing of Real-World Belzutifan-Related AEs Varies Between VHL-Associated Tumors and Sporadic RCC #oncology www.onclive.com/view/timing-...

Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer @drdanachase.bsky.social @uclahealth.org #GynecologicCancerAwarenessMonth www.onclive.com/view/dostarl...

The FDA Grants Priority Review to First-Line T-DXd Plus Pertuzumab in Metastatic HER2+ #BreastCancer www.onclive.com/view/fda-gra...

IIT Madras partners with LSU Health New Orleans, US, to Accelerate Global Health Innovation @lsu.bsky.social #Cancer #Healthcare www.onclive.com/view/iit-mad...

Advancements in #ProstateCancer Imaging, Minimally Invasive Approaches Require Cohesive Screening Recommendations to Optimize Patient Outcomes www.onclive.com/view/advance...

Personalized Approaches Are Emerging for GVHD in Hematologic Malignancies @weillcornell.bsky.social @societyofhemonc.bsky.social #SOHO2025 www.onclive.com/view/persona...

Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Are Crucial for #EndometrialCancer Risk Reduction www.onclive.com/view/spotlig...

Miss anything at #IMS2025? See which myeloma presentations and data stood out most to experts at the meeting. Sign up and read exclusive expert insights! #mmsm #oncology www.onclive.com/view/myeloma...

IberDd Demonstrates Positive Topline Efficacy in Relapsed/Refractory #MultipleMyeloma #oncology www.onclive.com/view/iberdd-...

INESSS Issues Positive Recommendation for the Reimbursement of Subcutaneous Nivolumab Across Solid Tumor Indications #oncology www.onclive.com/view/inesss-...

Linvoseltamab Adds Highly Effective Option in Later-Line Multiple Myeloma @winshipcancer.emory.edu #hematology #mmsm www.onclive.com/view/linvose...

Radioligand Therapy Sequencing, Novel Targets Continue to Shape Prostate Cancer Care and Research #ProstateCancerAwarenessMonth #pcsm #oncology www.onclive.com/view/radioli...

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes @roswellpark.bsky.social @columbiamed.bsky.social @jci-insight.bsky.social #lcsm #lungcancer #oncology www.onclive.com/view/study-l...

Giredestrant Plus Everolimus Meets Coprimary PFS End Points in Post–CDK Inhibitor ER+/HER2– Breast Cancer #bcsm #breastcancer #oncology www.onclive.com/view/giredes...

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights www.onclive.com/view/ai-powe...

Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/isa-vrd...

New T-DXd Data Have the Potential to Reorder ADC Sequencing in HER2+ Breast Cancer #oncology #bcsm #HER2breastcancer www.onclive.com/view/new-t-d...

BKd Produces Robust Responses in Relapsed/Refractory @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/bkd-pro...

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/belanta...

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma @myeloma-society.bsky.social #IMS25 #mmsm www.onclive.com/view/belanta...

ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/atlas-a...

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma @myeloma-society.bsky.social #IMS25 #mmsm www.onclive.com/view/subcuta...

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/daratum...

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/belanta...

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/stretch...

Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma @andrew02114.bsky.social @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/daratum...

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/belanta...

BREAKING🚨: FDA Approves Subcutaneous Pembrolizumab for Solid Tumors #oncology www.onclive.com/view/fda-app...